Treatment of chemotherapy-related anemia with erythropoietic agents: Current approaches and new paradigms

Seminars in Hematology

Volumn 41, Issue SUPPL. 7, 2004, Pages 9-16

  Waltzman, Roger J ^a  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RATING SCALE; REVIEW; UNITED STATES;

EID: 10444221027     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2004.09.003     Document Type: Article

References (50)

1. J.R. Adams, L.S. Elting, G.H. Lyman Use of erythropoietin in cancer patients Assessment of oncologists' practice patterns in the United States and other countries Am J Med 116 2004 28 34
2. Aranesp® (darbepoetin alfa) [package insert] 2004 Thousand Oaks CA, Amgen
3. D.W. Blayney, H. Spiridonidis, M.R. Fesen Darbepoetin alfa every 2 weeks to treat chemotherapy-induced anemia Experience in a randomized, open-label study 2003 Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3
4. C. Bokemeyer, K. Oechsle, J.T. Hartmann Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer Br J Cancer 87 2002 1066 1071
5. J.J. Caro, M. Salas, A. Ward Anemia as an independent prognostic factor for survival in patients with cancer A systematic, quantitative review Cancer 91 2001 2214 2221
6. D. Cella, M.J. Zagari, C. Vandoros Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population J Clin Oncol 21 2003 366 373
7. J. Chang, F. Couture Canadian Eprex Study Group Once weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy Proc Am Soc Clin Oncol 22 2003 727 (abstr 2923)
8. W. Cheung, N. Minton, K. Gunawardena Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly Eur J Clin Pharmacol 57 2001 411 418
9. J. Crawford, D. Cella, C.S. Cleeland Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy Cancer 95 2002 888 895
10. J. Crawford, F. Robert, M. Perry Epoetin alfa 40,000 U once weekly maintains hemoglobin in advanced non-small cell lung cancer patients receiving first-line chemotherapy Proc Am Soc Clin Oncol 22 2003 628 (abstr 2527)
11. G.D. Demetri, M. Kris, J. Wade Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group J Clin Oncol 16 1998 3412 3425
12. J.C. Egrie, J.K. Browne Development and characterization of novel erythropoiesis stimulating protein (NESP) Br J Cancer 84 suppl 1 2001 3 10
13. R.J. Ferguson, T.A. Ahles Low neuropsychologic performance among adult cancer survivors treated with chemotherapy Curr Neurol Neurosci Rep 3 2003 215 222
14. K.T. Francis Fitness assessment using step tests Compr Ther 13 1987 36 41
15. J.L. Gabrilove, C.S. Cleeland, R.B. Livingston Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 19 2001 2875 2882
16. J. Glaspy, R. Bukowski, D. Steinberg Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group J Clin Oncol 15 1997 1218 1234
17. J.A. Glaspy, J.A. Jadeja, G. Justice Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy Br J Cancer 87 2002 268 276
18. J.R. Gralow, C.A. Hudis, D. Williams Incremental improvements in QOL related to changes in Hb in breast cancer (BC) patients (Pts) receiving adjuvant chemotherapy (ADJCT) and QW epoetin alfa therapy Blood 102 2003 4392 (abstr)
19. M. Grogan, G.M. Thomas, I. Melamed The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix Cancer 15 86 1999 1528 1536
20. J.L. Groopman, L.M. Itri Chemotherapy induced anemia in adults Incidence and treatment J Natl Cancer Inst 91 1999 1616 1634
21. M. Hedenus, S. Hansen, K. Taylor Randomized, dose-finding study of darbepoetin alfa in anemic patients with lymphoproliferative malignancies Br J Haematol 119 2002 79
22. P.J. Hesketh, F. Arena, D. Patel A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies Cancer 100 2004 859 868
23. C. Hudis, D. Williams, J.R. Gralow Epoetin alfa maintains hemoglobin and quality of life in breast cancer patients receiving adjuvant chemotherapy Final report Proc Am Soc Clin Oncol 22 2003 767 (abstr 3084)
24. A.A. Jakubowski, H. Hurria, D. Williams Head-to-head comparison of epoetin alfa 40,000 U QW vs. darbepoetin alfa 200 mcg Q2W in anemic patients with cancer receiving chemotherapy Preliminary results Blood 102 2003 4391 (abstr)
25. J. Kirshner, M. Hatch, D.D. Hennessy Anemia in stage II and III breast cancer patients treated with adjuvant doxorubicin and cyclophosphamide chemotherapy Oncologist 9 2004 25 32
26. D. Kotasek, G. Steger, W. Faught Darbepoetin alfa administered every 3 weeks alleviates anemia in patients with solid tumors receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study Eur J Cancer 39 2003 2026 2034
27. T.J. Littlewood, E. Bajetta, J.W.R. Nortier Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 19 2001 2865 2874
28. G.B. Ludwig, P. Barrett-Lee, Krzakowski Prevalence and management of anemia in patients with hematologic malignancies and solid tumors Results from the European Cancer Anaemia Survey Blood 100 2002 234a 235a (abstr 884)
29. K. Münstedt, M. Völzing, R. Von Georgi Hemoglobin levels during radiation therapy and their influence on local control and survival of patients with endometrial carcinoma Oncol Rep 11 2004 711 717
30. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology, v.2.2004. Cancer and treatment-related anemia. Available at: http://www.e-nccn.com/professionals/physician_gls/PDF/anemia.pdf
31. J. O'Shaughnessy Chemotherapy-related cognitive dysfunction in breast cancer Semin Oncol Nurs 19 suppl 2 2003 17 24
32. J.A. O'Shaughnessy, S. Vukelja, M. Savin Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy Analysis of 6-month follow-up data 2002 Presented at the 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-December 14
33. D.L. Patrick, D.D. Gagnon, M.J. Zagari Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa Eur J Cancer 39 2003 335 345
34. J. Patton, M. Kuzur, W. Liggett Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy Oncologist 9 2004 90 96
35. PROCRIT® (epoetin alfa) [package insert] 2004 Ortho Biotech Products, L.P Bridgewater, NJ
36. I. Quirt, C. Robeson, C.Y. Lau Epoetin alfa in patients not on chemotherapy--Canadian data Semin Oncol 29 suppl 8 2002 75 80
37. I. Quirt, C. Robeson, C.Y. Lau Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy J Clin Oncol 19 2001 4126 4134
38. J.D. Rizzo, A.E. Lichtin, S.H. Woolf Use of epoetin in patients with cancer evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology J Clin Oncol 20 2002 1 25
39. J. Rosberg, P. Lefebvre, J. Fastenau Clinical significance of a < 1 gram/deciliter (g/dL) rise in hemoglobin (Hb) at week 4 (early response) or at week 8 during epoetin alfa (EPO) treatment 2003 Presented at the 45th Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9
40. L.S. Schwartzberg, L.K. Yee, F.M. Senecal Early results of a head-to-head comparison of darbepoetin alfa 200 mcg given every 2 weeks (Q2W) and epoetin alfa 40,000 U 2003 Presented at the 45th Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9
41. D. Shasha Once-weekly epoetin alfa improves quality of life in chemoradiation patients 2002 Presented at the 44th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), New Orleans, LA, October 6-10
42. D. Shasha, M.J. George, L.B. Harrison Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy Cancer 98 2003 1072 1079
43. D. Shasha, P. Homel, L.B. Harrison The additive effect of chemotherapy (CT) on the prevalence and severity of anemia in cancer patients receiving curative-intent radiation therapy (RT) 2003 Presented at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3
44. J.A. Sloan, T. Witzig, P. Silberstein Quality of life, blood transfusions, and toxicity, in anemic patients with advanced cancer receiving weekly erythropoietin while on chemotherapy Results from a phase III randomized double-blind placebo-controlled study Proc Am Soc Hematol 100 2002 287a (abstr)
45. R.E. Smith Jr, N.S. Tchekmedyian, D. Chan A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer Br J Cancer 88 2003 1851 1858
46. D.J. Straus, M. Testa, S.A. Riggs Early treatment with epoetin alfa improves anemia, quality of life, and productivity in patients with hematologic malignancies and mild anemia during chemotherapy 2003 Presented at the 45th Annual Meeting of the American Society of Hematology, San Diego, CA, December 6-9
47. F. Tas, Y. Eralp, M. Basarn Anemia in oncology practice Relation to diseases and their therapies Am J Clin Oncol 25 2002 371 379
48. S. Vadhan-Raj, B. Mirtsching, V. Charu Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks J Support Oncol 1 2003 131 138
49. J. Vansteenkiste, R. Pirker, B. Massuti Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 2002 1211 1220
50. R.J. Waltzman, M. Fesen, G.R. Justice Epoetin alfa 40,000 U QW vs darbepoetin alfa 200 mcg Q2W in anemic cancer patients receiving chemotherapy Preliminary results of a comparative trial Proc Am Soc Clin Oncol 23 2004 (abstr 8153)